Join NBTS’s campaign to raise awareness about the importance of biomarker testing and clinical trials for patients with brain tumors.
READ MOREPublished on January 28, 2014 in Press Release
Ann Kingston, PhD, brings more than two decades of experience in pharmaceutical research to leading brain tumor nonprofit
BOSTON, MA – National Brain Tumor Society, the largest nonprofit dedicated to the brain tumor community in the United States, today announced the appointment of Ann Kingston, PhD, as Assistant Director of Program Initiatives. Dr. Kingston will play an important role in the continuing development and execution of the Organization’s key programs related to drug development and clinical testing, including the Advancing Research to Treatments (ART) for brain tumors program.
“Ann’s experience working for top pharmaceutical companies will be invaluable as we continue to build our program initiatives focused on drug development,” said N. Paul TonThat, CEO, National Brain Tumor Society. “This hire further underscores our commitment to play an active role in bringing new, badly-needed brain tumor therapies to market and moving beyond the traditional charity model based solely on distributing grants.”
Dr. Kingston, a PhD in Biochemistry and Immunology, began her career as postdoctoral fellow for the National Institute for Medical Research (London, England), before moving on to a number of research appointments with both Eli Lilly and Company and Pfizer Inc. In these roles, she directed cross-site and cross-functional teams spanning the drug discovery pipeline from target validation to clinical evaluation of several CNS treatment candidates, and managed numerous industry/academia collaborations. Dr. Kingston is the co-inventor of five (5) biomedical patents and author of more than 60 peer-reviewed scientific papers, reviews, and articles.
Dr. Kingston is the latest addition to the Programs Department at the National Brain Tumor Society, as the Organization continues to build broad capacity to tackle the most significant issues impeding new therapy development for brain tumor patients. She joins a senior staff of accomplished professionals, including: Senior Director of Public Policy, David Arons, JD, formerly of the American Cancer Society; Associate Program Director, Jennifer Helfer, PhD, a former postdoctoral researcher in biochemistry at Boston University School of Medicine; Director of Program Initiatives, Michele Rhee, MBA, MPH, who most recently worked as a consultant for Health Advances, a healthcare and life sciences consulting firm; Associate Director of Public Policy, Lainey Titus Samant, formerly of the Massachusetts Nursing Association; and Senior Director of Research and Managing Director of the Defeat GBM Research Collaborative, Carrie Treadwell, who helped build the Organization’s research program.
